Parallel Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Parallel Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-750	Closed	-$1.66K	–	3520
2023 Q2	$1.66K	Buy	+750	New	+$1.55K	﹤0.01%	2805
2019 Q3	–	Sell	-310	Closed	-$1K	–	2534
2019 Q2	$1K	Sell	310 -2,751	-90%	-$13.1K	﹤0.01%	2270
2019 Q1	$16K	Buy	3,061 +900	+42%	+$5.81K	﹤0.01%	1322
2018 Q4	$11K	Buy	2,161 +300	+16%	+$2.28K	﹤0.01%	1312
2018 Q3	$18K	Buy	1,861 +1,161	+166%	+$11.7K	﹤0.01%	1205
2018 Q2	$7K	Buy	+700	New	+$7.92K	﹤0.01%	1502

Parallel Advisors's PRTK Position: Q3 2023 in Review

Parallel Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 750 shares — an estimated $1.66K sold.

Parallel Advisors first reported a position in PRTK in Q2 2018 and held it in 6 quarters. The position peaked at $18K in Q3 2018. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.

Parallel Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Parallel Advisors sold 750 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $1.66K.
Parallel Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2018 and held it in 6 quarters.
Parallel Advisors's Paratek Pharmaceuticals, Inc. position peaked at $18K in Q3 2018.
0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.

Based on Parallel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.